学校法人順天堂　研究者情報データベース:::研究業績詳細:::

HOME　＞　研究業績詳細

研究業績詳細

射場敏明（イバトシアキ）

研究テーマ	sepsis, coagulopathy, microcirculation, multiple organ failure, COVID-19, heatstroke
研究業績（論文）	【英文原著、総説】 1. Gando S, Saitoh D, Ogura H, Mayumi T, Koseki K, Ikeda T, Ishikura H, Iba T, Ueyama M, Eguchi Y, Ohtomo Y, Okamoto K, Kushimoto S, Endo S, Shimazaki S; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: Results of a multicenter, prospective survey. Crit Care Med 36: 145-150, 2008 2. Iba T, Miyasho T: Danaparoid sodium attenuates the increase in inflammatory cytokines and preserves organ function in endotoxemic rats. Crit Care 12: R86-91, 2008 3. Kushimoto S, Gando S, Saitoh D, Ogura H, Mayumi T, Koseki K, Ikeda T, Ishikura H, Iba T, Ueyama M, Eguchi Y, Otomo Y, Okamoto K, Endo S, Shimazaki S: Clinical course and outcome of disseminated intravascular coagulation diagnosed by Japanese Association for Acute Medicine criteria. Thromb Haemost 100: 1099-1105, 2008 4. Iba T, Ujike Y: Therapeutic approach to the septic organ dysfunction by anticoagulant therapy. Jpn J Thromb Hemost 19: 384-396, 2008 5. Gando S, Saitoh D, Ogura H, Mayumi T, Koseki K, Ikeda T, Ishikura H, Iba T, Ueyama M, Eguchi Y, Otomo Y, Okamoto K, Kushimoto S, Endo S, Shimazaki S; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. Disseminated intravascular coagulation (DIC) diagnosed based on the Japanese Association for Acute Medicine criteria is a dependent continuum to overt DIC in patients with sepsis. Thromb Res 123: 715-718, 2009 6. Iba T, Takayama T: Enoxaparin attenuates endothelial damage with less bleeding compared to unfractionated heparin in endotoxemic rats. Shock 32: 530-534, 2009 7. Iba T, Nakarai E, Takayama T, Nakajima K, Sasaoka T, Ohno Y: Combination effect of antithrombin and recombinant human soluble thrombomodulin in an LPS induced rat sepsis model. Critical Care 13: R203-209, 2009 8. Wada H, Asakura H, Okamoto K, Iba T, Uchiyama T, Kawasugi K, Koga S, Mayumi T, Koike K, Gando S, Kushimoto S, Seki Y, Madoiwa S, Maruyama I, Yoshioka A; Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 125: 6-11, 2009 9. Iba T, Asakura H: Comparison between British and Japanese guidelines for the diagnosis and treatment of disseminated intravascular coagulation. Br J Haematol Epub 2010 10. Okamoto K, Wada H, Hatada T, Uchiyama T, Kawasugi K, Mayumi T, Gando S, Kushimoto S, Seki Y, Madoiwa S, Asakura H, Koga S, Iba T, Maruyama I; Japanese Society of Thrombosis Hemostasis/DIC subcommittee.Frequency and hemostatic abnormalities in pre-DIC patients. Thromb Res. 126: 74-78, 2010 11. Kawasaki S, Iba T: The current status of sepsis research in Japan and its international comparison. Juntendo Medical J 56: 334-338, 2010 12. Iba T, Okamoto K, Kawasaki S, Nakarai E, Miyasho T. Effect of hemoperfusion using polymyxin B-immobilized fibers on non-shock rat sepsis model. J Surg Res. 2011;171(2):755-61 13. Yanagawa Y, Tajima M, Ohara K, Aihara K, Matsuda S, Iba T. A case of cardiac arrest with ST elevation induced by contrast medium. Am J Emerg Med. 2012;30(9):2083.e3-4 14. Iba T; Japanese Association for Acute Medicine DIC Study Group. The meanings of DIC diagnostic criteria. Thromb Res. 2012;129(5):e269-70 15. Iba T, Okamoto K, Ohike T, Tajirika T, Aihara K, Watanabe S, Kayhanian H. Enoxaparin and fondaparinux attenuates endothelial damage in endotoxemic rats. J Trauma Acute Care Surg. 2012;72(1):177-82 16. Iba T, Aihara K, Kawasaki S, Yanagawa Y, Niwa K, Ohsaka A. Formation of the venous thrombus after venous occlusion in the experimental mouse model of metabolic syndrome. Thromb Res. 2012;129(5):e246-50 17. Iba T, Saito D, Wada H, Asakura H. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a prospective multicenter survey. Thromb Res. 2012;130(3):e129-33 18. Yanagawa Y, Hirano Y, Kato H, Iba T. The absence of typical pneumonia symptoms in a patient with rheumatoid arthritis during tocilizumab and steroid treatment. BMJ Case Rep. 2012 May 23 19. Iba T, Aihara K, Watanabe S, Yanagawa Y, Takemoto M, Yamada A, Yang D. Recombinant thrombomodulin improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat LPS model. Thromb Res. 2013;131(4):295-9 20. Iba T, Nagaoka I, Boulat M. The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation. Thromb Res. 2013;131(5):383-9. 21. Iba T, Aihara K, Watanabe S, Yanagawa Y, Yamada A, Koichiro N, Ohsaka A. Factor Xa inhibitor attenuates leukocyte adhesion and thrombus formation in an experimental mouse model of the metabolic syndrome. Cardiovasc Ther. 2013 May 1 22. Yanagawa Y, Yoshihara T, Kato H, Iba T, Tanaka H. Significance of urinary incontinence, age, and consciousness level on arrival among patients with stroke. J Emerg Trauma Shock. 2013;6(2):83-6 23. Iba T, Aihara K, Watanabe S, Yanagawa Y, Takemoto M, Yamada A, Yang D. Recombinant thrombomodulin improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat LPS model. Thromb Res. 2013;131(4):295-9. 24. Iba T, Aihara K, Watanabe S, Yanagawa Y, Yamada A, Koichiro N, Ohsaka A. Factor Xa inhibitor attenuates leukocyte adhesion and thrombus formation in an experimental mouse model of the metabolic syndrome. Cardiovasc Ther. 2013;31(5):280-284. 25. Yanagawa Y, Yoshihara T, Kato H, Iba T, Tanaka H. Significance of urinary incontinence, age, and consciousness level on arrival among patients with stroke. J Emerg Trauma Shock. 2013;6(2):83-6. 26. Iba T, Miki T, Hashiguchi N, Yamada A, Nagaoka I: Combination of antithrombin and recombinant thrombomodulin attenuates leukocyte-endothelial interaction and suppresses the increase of intrinsic DAMPs in endotoxemic rats. J Surg Res 2014 187(2):581-586. 27. Gando S, Saitoh D, Ishikura H, Ueyama M, Otomo Y, Oda S, Kushimoto S, Tanjoh K, Mayumi T, Ikeda T, Iba T, Eguchi Y, Okamoto K, Ogura H, Koseki K, Sakamoto Y, Takayama Y, Shirai K, Takasu O, Inoue Y, Mashiko K, Tsubota T, Endo S: A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care 2013 ;17(6):R297 28. Iba T, Nagaoka I, Yamada A, Nagayama M, Miki T: Effect of Hemoperfusion Using Polymyxin B-immobilized Fibers on Acute Lung Injury in a Rat Sepsis Model. Int J Med Sci 2014;11(3):255-261. 29. Hu Z, Murakami T, Suzuki K, Tamura H, Kuwahara-Arai K, Iba T, Nagaoka I. Antimicrobial Cathelicidin Peptide LL-37 Inhibits the LPS/ATP-Induced Pyroptosis of Macrophages by Dual Mechanism. PLoS One 2014;9(1):e85765 30. Iba T, Aihara K, Yamada A, Nagayama M, Tabe Y, Ohsaka A. Rivaroxaban attenuates leukocyte adhesion in the microvasculature and thrombus formation in an experimental mouse model of type 2 diabetes mellitus. Thromb Res 2014;133(2):276-280. 31. Iba T, Miki T, Hashiguchi N, Tabe Y, Nagaoka I. Combination of antithrombin and recombinant thrombomodulin modulates neutorophil cell-death and decreases circulating DAMPs levels in endotoxemic rats. Thromb Res 2014;134(1):169-173. 32. Iba T, Saitoh D, Wada H, Asakura H: Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey. Critical Care 2014;18(5):497. 33. Iba T, Saitoh D, Gando S, Thachil J: The usefulness of antithrombin activity monitoring during antithrombin supplementation in patients with sepsis-associated disseminated intravascular coagulation. Thromb Res 2015;135(5):897-901. 34. Iba T, Nagakari K: The effect of plasma-derived activated protein C on leukocyte cell-death and vascular endothelial damage. Thromb Res 2015;135(5):963-9. 35. Miki T, Iba. Kinetics of Circulating Damage-Associated Molecular Patterns in Sepsis.J Immunol Res 2015;2015:424575. doi: 10.1155/2015/424575. 36. Yuri M, Tabe Y, Tsuchiya K, Sadatsuki R, Aoki J, Horii T, Iba T, Ohsaka A.Evaluation of Factor Xa-Specific Chromogenic Substrate Assays and the Determination of Pharmacokinetics of Fondaparinux. Clin Appl Thromb Hemost. Jul 15. pii: 1076029615595878. 37. Iba T, Hashiguchi N, Nagaoka I, Tabe Y, Kadota K, Sato K. Heparins attenuated histone-mediated cytotoxicity in vitro and improved the survival in a rat model of histone-induced organ dysfunction. Intensive Care Med Exp. 2015;3(1):36. 38. Iba T, Ito T, Maruyama I, Jilma B, Brenner T, Müller MCA, Juffermans NP, Thachil J. Potential diagnostic markers for disseminated intravascular coagulation of sepsis. Blood Reviews 2016;30(2):149-155. 39. Iba T, Thachil J. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a Japanese perspective. International Journal of hematology 2016;103(3):253-61. 40. Liaw P, Ito T, Iba T, Thachil J, Zeerleder S. DAMP and DIC: the role of extracellular DNA and DNA-binding proteins in the pathogenesis of DIC. Blood Reviews 2015 Dec 31. pii: S0268-960X(15)00097-1. doi: 10.1016/j.blre.2015.12.004. 41. Iba T, Hamakubo T, Nagaoka I, Sato K. Physiological levels of pentraxin 3 and albumin attenuate vascular endothelial cell damage induced by histone H3 in vitro. Microcirculation 2016;23(3):240-247. 42. Nagakari K. Iba T, Emmi M. Prothrombin time tests for the monitoring of direct oral anticoagulants and their evaluation as indicators of the reversal effect. Clin Appl Thromb Hemost 2016 Mar 16. 43. Iba T, Emmi M, Hiki M, Nagayama M, Aihara K, Tabe Y, Yuri M, Ohsaka A. Comparison of prothrombin tests used in the monitoring of edoxaban and their evaluation as indicators of reversal effect. Int J Hematol 2016;103(6): 665-672. 44. Iba T, Saitoh D, Gando S, Ikeda T, Anan H, Oda S, Kitamura N, Mori S, Kotan J, Kuroda Y. Efficacy and bleeding risk of antithrombin supplementation in patients with septic disseminated intravascular coagulation: A third survey. Clin Appl Thromb Hemost 2016 pii: 1076029616648405. 45. Iba T, Gando S, Saitoh D, Wada H, Di Nisio M, Thachil J. Antithrombin supplementation and risk of bleeding in patients with sepsis-associated disseminated intravascular coagulation. Thromb Res 2016;145:46-50. 46. Iba T, Di Nisio M, Thachi J, Wada H, Asakura H, Sato K, Kitamura N, Saitoh D. Revision of the Japanese Association for Acute Medicine (JAAM)-disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity. Crit Care 2016;20:287. 47. Iba T. Glycocalyx regulates the intravascular hemostasis. Juntendo Medical J 2016, 62(4):330-335. 48. Iba T, Thachil J. Is antithrombin III for sepsis-associated disseminated intravascular coagulation really ineffective? Intensive Care Med 2016　42(7):1193-1194. 49. Iba T, Thachil J. Is protein C zymogen really ineffective for ALL cases of sepsis including septic DIC? Intensive Care Med 2016　43(1):152-153. 50. Iba T. Bleeding complications of anticoagulant therapy in sepsis-induced disseminated intravascular coagulation. Crit Care 2016;20:307. 51. Hu Z, Murakami T, Tamura H, Reich J, Kuwahara-Arai K, Iba T, Tabe Y, Nagaoka I. Neutrophil extracellular traps induce IL-1β production by macrophages in combination with lipopolysaccharide. Int J Mol Med. 2017;39(3):549-558. 52. Takehara K, Murakami T, Kuwahara-Arai K, Iba T, Nagaoka I, Sakamoto K. Evaluation of the effect of recombinant thrombomodulin on a lipopolysaccharide‑induced murine sepsis model. Experimental and Therapeutic Medicine. 2017;13(6):2969-2974. 53. Iba T, Sasaki T, Ohno T, Sato K, Nagaoka I, Thachil J. β-Antithrombin attenuates vascular endothelial cell damage induced by histone more efficiently than α-antithrombin. Thromb Haemost Open 2017 54. Iba T, Di Nisio M, Thachil J, Wada H, Asakura H, Sato K, Saitoh D. A proposal of the modification of Japanese Society on Thrombosis and Hemostasis (JSTH)-disseminated intravascular coagulation (DIC) diagnostic criteria for sepsis-associated DIC. Clin Appl Thromb Hemost 2017doi: 10.1177/1076029617720069. 55. Iba T, Di Nisio M, Levy J, Kitamura N, Thachil J. New Criteria for Sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open 2017;7:e017046. 56. Hosoda H, Nakamura K, Hu Z, Tamura H, Reich J, Kuwahara-Arai K, Iba T, Tabe Y, Nagaoaka I. Mol Med Rep. 2017 Aug 17. doi: 10.3892/mmr.2017.7267. 57. Iba T, Hagiwara A, Saitoh D, Anan H, Ueki Y, Sato K, Gando S. Effects of combination therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation. Annals of Intensive Care 2017, 7:110. 58. Iba T, Levy, J. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost 2017, DOI:10.1111/jth.13911 59. Iba T, Thachil, J. Clinical significance of measuring plasminogen activator inhibitor-1 in sepsis. J Intensive Care 2017;5:56. 60. Thachil J, Iba T. The application of anticoagulant therapy to sepsis. J Intensive Care. 2017;5:32. 61. Iba T, Fowler L. Is polymyxin B-immobilized fiber column ineffective for septic shock? A discussion on the press release for EUPHRATES trial. J Intensive Care 2017;5:40. 62. Iba T, Hirota T, Sato K, Nagaoka I. Protective effect of a newly developed fucose-deficient recombinant antithrombin against histone-induced endothelial damage. Int J Hematol 2018;107(5):528-534. 63. Iba T, Arakawa M, Levy JH, Yamakawa K, Koami H, Hifumi T, Sato K. Sepsis-Induced Coagulopathy and Japanese Association for Acute Medicine DIC in Coagulopathic Patients with Decreased Antithrombin and Treated by Antithrombin. Clin Appl Thromb Hemost. 2018;24(7):1020-1026. 64. Iba T, Arakawa M, Di Nisio M, Gando S, Anan H, Sato K, Ueki Y, Levy JH, Thachil J. Newly Proposed Sepsis-Induced Coagulopathy Precedes International Society on Thrombosis and Haemostasis Overt-Disseminated Intravascular Coagulation and Predicts High Mortality. J Intensive Care Med. 2018 Jan 1:885066618773679. 65. Suzuki K, Wada H, Imai H, Iba T. A reevaluation of the D-dimer cut-off value for making a diagnosis using the ISTH overt-DIC diagnostic criteria: communication from the SSC of the ISTH. J Thromb Haemost 66. Nishida O, Ogura H, Egi M, Fujishima S, Hayashi Y, Iba T, et al. The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016). Acute Med Surg. 2018;5(1):3-89. 67. Wada H, Matsumoto T, Suzuki K, Imai H, Katayama N, Iba T, Matsumoto M. Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thromb J. 2018;11;16:14. 68. Iba T, Arakawa M, Ohchi Y, Arai T, Sato K, Wada H, Levy JH. Prediction of early death in patients with sepsis-associated coagulation disorder treated with antithrombin supplementation. Clin Appl Thromb Hemost. 2018;1076029618797474. doi: 10.1177/1076029618797474 69. Iba T, Levy JH, Hirota T, Hiki M, Sato K, Murakami T, Nagaoka I. Protection of the endothelial glycocalyx by antithrombin in an endotoxin-induced rat model of sepsis. Thromb Res. 2018; 171:1-6. 70. Iba T. Tanaka H. Oh, how hard it is to open the gate of sepsis trial: lessons from SCARLET. Acute Med Surg. 2018;6(1):3-4. 71. Demma LJ, Faraoni D, Winkler AM, Iba T, Levy JH. Predicting mortality in patients with disseminated intravascular coagulation after cardiopulmonary bypass surgery by utilizing two scoring systems. Blood Coagul Fibrinolysis. 2018;30(1):11-16. 72. Iba T, Ogura H. Role of extracellular vesicles in the development of sepsis-induced coagulopathy. J Intensive Care. 2018;6(1):68. 73. Iba T, Levy JH. Derangement of the endothelial glycocalyx in sepsis. J Thromb Haemost. 2018, 17(2):283-294. 74. Iba T, Levy JH, Wada H, Thachil J, Warkentin T, Levi M; Subcommittee on Disseminated Intravascular Coagulation. Differential diagnoses for sepsis‐induced disseminated intravascular coagulation: communication from the SSC of the ISTH. J Thromb Haemost. 2018;17(2):415-419. 75. Iba T, Arakawa M, Mochizuki K, Nishida O, Wada H, Levy JH. Usefulness of Measuring Changes in SOFA Score for the Prediction of 28-Day Mortality in Patients With Sepsis-Associated Disseminated Intravascular Coagulation. Clin Appl Thromb Hemost. 2019;25:1076029618824044. 76. Fukushima Y, Yamada A, Imoto N, Iba T. Does TeamSTEPPS affect psychological status? Int J Health Care Qual Assur. 2019;32(1):11-20. 77. Iba T, Levy JH, Thachil J, Wada H, Levi M; Scientific and Standardization Committee on DIC of the International Society on Thrombosis and Haemostasis. The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases. Thromb Res. 2019;179:11-14. 78. Iba T, Levy JH, Yamakawa K, Thachil J, Warkentin TE, Levi M; Scientific and Standardization Committee on DIC of the International Society on Thrombosis and Haemostasis. Proposal of a two-step process for the diagnosis of sepsis-induced disseminated intravascular coagulation. J Thromb Haemost. 2019;17(8):1265-1268. 79. Iba T, Levy JH, Raj A, Warkentin TE. Advance in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. J Clin Med. 2019;8(5). pii: E728. 80. Iba T, Klein DJ. The wind changed direction and the big river still flows: from EUPHRATES to TIGRIS. J Intensive Care. 2019;7:31. 81. Iba T, Watanabe E, Umemura Y, Wada T, Hayashida K, Kushimoto S; Japanese Surviving Sepsis Campaign Guideline Working Group for disseminated intravascular coagulation, Wada H. Sepsis-associated disseminated intravascular coagulation and its differential diagnoses. J Intensive Care. 2019;7:32. 82. Rabinovich A, Abdul-Kadir R, Thachil J, Iba T, Othman M, Erez O. DIC in obstetrics: Diagnostic score, highlights in management, and international registry-communication from the DIC and Women's Health SSCs of the International Society of Thrombosis and Haemostasis. J Thromb Haemost. 2019;17(9):1562-1566. 83. Suzuki K, Wada H, Matsumoto T, Ikejiri M, Ohishi K, Yamashita Y, Imai H, Iba T, Katayama N. Usefulness of the APTT waveform for the diagnosis of DIC and prediction of the outcome or bleeding risk. Thromb J. 2019;17:12. 84. Iba T, Umemura Y, Watanabe E, Wada T, Hayashida K, Kushimoto S; Japanese Surviving Sepsis Campaign Guideline Working Group for disseminated intravascular coagulation. Diagnosis of sepsis-induced disseminated intravascular coagulation and coagulopathy. Acute Med Surg. 2019;6(3):223-232. 85. Levy JH, Ghadimi K, Faraoni D, van Diepen S, Levy B, Hotchkiss R, Connors JM, Iba T, Warkentin TE. Ischemic limb necrosis in septic shock: What is the role of high-dose vasopressor therapy? J Thromb Haemost. 2019;17(11):1973-1978. 86. Iba T, Levy JH, Warkentin TE, Thachil J, van der Poll T, Levi M; Scientific and Standardization Committee on DIC, and the Scientific and Standardization Committee on Perioperative and Critical Care of the International Society on Thrombosis and Haemostasis. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989-1994. 87. Ito T, Thachil J, Asakura H, Levy JH, Iba T. Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential. Crit Care. 2019;23(1):280. 88. Aoki J, Sakamoto K, Takahashi R, Niwa K, Ishiyama S, Sugimoto K, Kamiyama H, Takahashi M, Kojima Y, Goto M, Tomiki Y, Iba T. Current status of venous thromboembolism development during the perioperative period for colorectal cancer, its prevention with enoxaparin, and monitoring methods. Ther Clin Risk Manag. 2019;15:791-802. 89. Iba T, Levi M, Levy JH. Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Semin Thromb Hemost. 2019 Aug 23. doi: 10.1055/s-0039-1694995. 90. Yamakawa K, Levy JH, Iba T. Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis. Crit Care. 2019;5;23(1):302. 91. Hayashi N, Yamaguchi S, Rodenburg F, Ying Wong S, Ujimoto K, Miki T, Iba T. Multiple biomarkers of sepsis identified by novel time-lapse proteomics of patient serum. PLoS One. 2019;14(9):e0222403. 92. Iba T, Levy JH. Sepsis-induced Coagulopathy and Disseminated Intravascular Coagulation. Anesthesiology. 2020;132(5):1238-1245. 93. Moore HB, Gando S, Iba T, Kim PY, Yeh CH, Brohi K, Hunt BJ, Levy JH, Draxler DF, Stanworth S, Görlinger K, Neal MD, Schreiber MA, Barrett CD, Medcalf RL, Moore EE, Mutch NJ, Thachil J, Urano T, Thomas S, Scărlătescu E, Walsh M; Subcommittees on Fibrinolysis, Disseminated Intravascular Coagulation, and Perioperative and Critical Care Thrombosis and Hemostasis. Defining trauma-induced coagulopathy with respect to future implications for patient management: Communication from the SSC of the ISTH. J Thromb Haemost. 2020;18(3):740-747. 94. Hirota T, Levy JH, Iba T. The influence of hyperglycemia on neutrophil extracellular trap formation and endothelial glycocalyx damage in a mouse model of type 2 diabetes. Microcirculation. 2020;27(5):e12617. 95. Valeriani E, Squizzato A, Gallo A, Porreca E, Vincent JL, Iba T, Hagiwara A, Di Nisio M. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy: a systematic review and meta-analysis. J Thromb Haemost. 2020;18(7):1618-1625. 96. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. DOACs and 'newer' haemophilia therapies in COVID-19. J Thromb Haemost. 2020;18(7):1795-1796. 97. Thachil J, Tang N, Gando S, Falanga A, Levi M, Clark C, Iba T. Laboratory haemostasis monitoring in COVID-19. J Thromb Haemost. 2020;18(8):2058-2060. 98. Thachil J, Tang N, Gando S, Falanga A, Levi M, Clark C, Iba T, Cattaneo M. Type and dose of heparin in COVID-19. J Thromb Haemost. 2020;18(8):2063-2064. 99. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-1026. 100. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;S2352-3026(20)30145-9. 101. Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T, Levi M, Samama CM, Thachil J, Giannis D, Douketis JD. Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19. J Thromb Haemost. 2020;18(8):1859-1865. 102. Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of Coronavirus Disease 2019. Crit Care Med. 2020;48(9):1358-1364. 103. Iba T, Levy JH, Warkentin TE, Thachil J, van der Poll T, Levi M. RE: The prothrombin time ratio is not a more effective marker for evaluating sepsis-induced coagulopathy than fibrin-related markers: Response to the Letter-to-the-Editor by Dr Wada. J Thromb Haemost. 2020;18(6):1507-1509. 104. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24(1):360. 105. Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. J Thromb Haemost. 2020;18(9):2103-2109. 106. Kumagai Y, Murakami T, Kuwahara-Arai, Iba T, Reich J, Nagaoka I. Antimicrobial peptide LL-37 ameliorates a murine sepsis model via the induction of microvesicle release from neutrophils. Innate Immun. 2020 Jun 29:1753425920936754. 107. Rabinovich A, Abdul-Kadir R, Thachil J, Iba T, Othman M, Erez O. Reply to "Errors in the diagnosis for DIC due to a statistical misunderstanding". J Thromb Haemost. 2020;18(7):1792-1793. 108. Kadir RA, Kobayashi T, Iba T, Erez O, Thachil J, Kazi S, Malinowski AK, Othman M. COVID-19 Coagulopathy in Pregnancy: Critical Review, Preliminary Recommendations and ISTH Registry - Communication from the ISTH SSC for Women's Health. J Thromb Haemost. 2020 Aug 26. doi: 10.1111/jth.15072. 109. Thachil J, Juffermans NP, Ranucci M, Connors JM, Warkentin TE, Ortel TL, Levi M, Iba T, Levy JH. ISTH DIC subcommittee communication on anticoagulation in COVID-19. J Thromb Haemost. 2020;18(9):2138-2144. 110. Squizzato A, Gallo A, Levi M, Iba T, Levy JH, Erez O, Ten Cate H, Solh Z, Gando S, Vicente V, Di Nisio M. Underlying disorders of disseminated intravascular coagulation: Communication from the ISTH SSC Subcommittees on Disseminated Intravascular Coagulation and Perioperative and Critical Care Thrombosis and Hemostasis. J Thromb Haemost. 2020;18(9):2400-2407. 111. Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm Res. 2020 Dec;69(12):1181-1189. 112. Iba T, Levy JH, Levi M, Connors JM, Thachil J. The authors reply. Crit Care Med. 2020 Oct;48(10):e989-e990. 113. Iba T, Levy JH, Levi M, Connors JM, Thachil J. The authors reply. Crit Care Med. 2020 Nov;48(11):e1160-e1161. 114. Iba T. Thrombin-Antithrombin System. H.B. Moore, et al. (eds.) Trauma-Induced Coagulopathy, Springer Nature Switzerland AG2021, pp43-51. 115. Levy JH, Iba T, Connors JM. Vascular injury in acute infections and COVID-19: everything old is new again. Trends Cardiovasc Med. 2020 Oct 28:S1050-1738(20)30134-1. 116.　Levy JH, Iba T, Connors JM. Editorial commentary: Vascular injury in acute infections and COVID-19: everything old is new again. Trends Cardiovasc Med. 2021 Jan;31(1):6-7. 117.　Iba T, Levy JH, Aihara K, Kadota K, Tanaka H, Sato K, Nagaoka I. Newly Developed Recombinant Antithrombin Protects the Endothelial Glycocalyx in an Endotoxin-Induced Rat Model of Sepsis. Int J Mol Sci. 2020 Dec 26;22(1):176. 118.　Iba T, Connors JM, Nagaoka I, Levy JH. Recent advances in the research and management of sepsis-associated DIC. Int J Hematol. 2021 Jan;113(1):24-33. 119.　Iba T, Warkentin TE, Thachil J, Levi M, Levy JH. Proposal of the Definition for COVID-19-Associated Coagulopathy. J Clin Med. 2021 Jan 7;10(2):E191. 120.　Iba T, Connors JM, Spyropoulos AC, Wada H, Levy JH. Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered? Int J Hematol. 2021 Jan 20. doi: 10.1007/s12185-021-03078-x. 121. Connors JM, Iba T, Gandhi RT. Thrombosis and COVID-19: Controversies and (Tentative) Conclusions. Clin Infect Dis. 2021 Feb 4:ciab096. doi: 10.1093/cid/ciab096. 122. Kawasugi K, Wada H, Honda G, Kawano N, Uchiyama T, Madoiwa S, Takezako N, Suzuki K, Seki Y, Ikezoe T, Iba T, Okamoto K. Hypofibrinogenemia is associated with a high degree of risk in infectious diseases: a post-hoc analysis of post-marketing surveillance of patients with disseminated intravascular coagulation treated with thrombomodulin alfa. Thromb J. 2021 Feb 25;19(1):12. 123. Hayashi N, Sawada Y, Ujimoto K, Yamaguchi S, Sato Y, Miki T, Nakada, Iba T. Diagnosis of Sepsis by AI-Aided Proteomics Using 2D Electrophoresis Images of Patient Serum Incorporating Transfer Learning for Deep Neural Networks. Applied Sciences. 2021, 11(4), 1967. 124. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. Managing thrombosis and cardiovascular complications of COVID-19: Answering the questions in COVID-19-associated coagulopathy. Expert Rev Respir Med. 2021 Aug;15(8):1003-1011. 125. Iba T, Warkentin TE, Connors JM, Levy JH. Therapeutic strategies in patients with coagulopathy and disseminated intravascular coagulation: awareness of the phase-dependent characteristics. Minerva Med. 2021 Mar 12. doi: 10.23736/S0026-4806.21.07469-3. 126. Levy JH, Iba T, Gardiner EE. Endothelial Injury in COVID-19 and Acute Infections: Putting the Pieces of the Puzzle Together. Arterioscler Thromb Vasc Biol. 2021 Apr 1:ATVBAHA121316101. doi: 10.1161/ATVBAHA.121.316101. 127. Arakawa M, Levy JH, Fujimori K, Kondo K, Iba T. A new SOFA score calculation to improve the predictive performance for mortality in sepsis-associated disseminated intravascular coagulopathy patients. J Crit Care. 2021 Mar 22;64:108-113. 128. Mitaka C, Kusao M, Kawagoe I, Satoh D, Iba T, Ronco C. Impact of Extended Duration of Polymyxin B-Immobilized Fiber Column Direct Hemoperfusion on Hemodynamics, Vasoactive Substance Requirement, and Pulmonary Oxygenation in Patients with Sepsis: An Observational Study. Blood Purif. 2021 Apr 28:1-8. 129. Yamamoto A, Wada H, Ichkawa Y, Tanaka M, Tashiro H, Shiraki K, Shimpo H, Yamashita Y, Mastumoto T, Shimaoka M, Iba T, Suzuki-Inoue K. Soluble C-Type Lectin-Like Receptor 2 Is a Biomarker for Disseminated Intravascular Coagulation. J Clin Med. 2021 Jun 28;10(13):2860. 130. Iba T, Levy JH, Warkentin TE. Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia. Crit Care Med. 2021 Jul 13. doi: 10.1097/CCM.0000000000005211. 131. Levy JH, Iba T, Olson LB, Corey KM, Ghadimi K, Connors JM. COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations. Int J Lab Hematol. 2021 Jul;43 Suppl 1:29-35. 132. Iba T, Levy JH, Levi M. Viral-induced inflammatory coagulation disorders: Preparing for another epidemic. Thromb Haemost. 2021 Jul 30. doi: 10.1055/a-1562-7599. 133. Iba T, Umemura Y, Wada H, Levy H. The Roles of Coagulation Disorder and Microthrombosis in Sepsis: Pathophysiology, Diagnosis, and Treatment. Arch Med Res. 2021 Jul 31:S0188-4409(21)00162-4. 134. Egi M, Ogura H, Yatabe T, Atagi K, Inoue S, Iba T, et al. The Japanese Clini20.cal Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J-SSCG 2020). J Intensive Care. 2021 Aug 25;9(1):53. 135. Iba T, Levy JH. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia. Trends Cardiovasc Med. 2021 Aug 26:S1050-1738(21)00096-7. doi: 10.1016/j.tcm.2021.08.012. 136. Mitaka C, Iba T, Ronco C. Polymyxin B-Immobilized Fiber Column Direct Hemoperfusion for Micro-Preemie Infants with Septic Shock. Is Extended Duration Better than Early Start? Comment to the Letter to the Editor of Nishizaki and Colleagues. Blood Purif. 2021 Sep 16:1-2. doi: 10.1159/000518904. 137. Iba T, Levy JH, Warkentin TE. Pitfalls in Diagnosing Vaccine-Induced Immune Thrombotic Thrombocytopenia. Crit Care Med. 2021 Sep 24. doi: 10.1097/CCM.0000000000005371. 138. Iba T, Nishida O, Levy JH, Levi M. Nevertheless, the importance of coagulation abnormalities should be emphasized in international sepsis guidelines. J Intensive Care. 2022 Jan 21;10(1):4. 139. Iba T, Connors JM, Levi M, Levy JH. Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient management. EClinicalMedicine. 2022 DOI:https://doi.org/10.1016/j.eclinm.2022.101276 140. Iba T, Levy JH. Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination. Trends Cardiovasc Med. 2022 Feb 22:S1050-1738(22)00038-X. 141. Wada H, Ichikawa Y, Ezaki M, Yamamoto A, Tomida M, Yoshida M, Fukui S, Moritani I, Shiraki K, Shimaoka M, Iba T, Suzuki-Inoue K, Shimpo H. Elevated Plasma Soluble C-Type Lectin-like Receptor 2 Is Associated with the Worsening of Coronavirus Disease 2019. J Clin Med. 2022 Feb 14;11(4):985. 142. Iba T, Wada H, Levy JH. Platelet Activation and Thrombosis in COVID-19. Semin Thromb Hemost. 2022 Jun 23. 143. Connors JM, Iba T. Vaccine-induced immune thrombotic thrombocytopenia and patients with cancer Thrombosis Research 2022 May; 213(Suppl 1):S77-S83. 144. Schulman S, Sholzberg M, Spyropoulos AC, Zarychanski R, Resnick HE, Bradbury CA, Broxmeyer L, Connors JM, Falanga A, Iba T, Kaatz S, Levy JH, Middeldorp S, Minichiello T, Ramacciotti E, Samama CM, Thachil J; International Society on Thrombosis and Haemostasis. ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost. 2022 Oct;20(10):2214-2225. 145. Iba T, Levi M, Levy JH. Intracellular communication and immunothrombosis in sepsis. J Thromb Haemost. 2022 Aug 17. doi: 10.1111/jth.15852. 146. Iba T, Helms J, Levi M, Levy JH. The role of platelets in heat-related illness and heat-induced coagulopathy. Thromb Res. 2022 Aug 17:S0049-3848(22)00342-5. 147. Iba T, Sawada T, Kondo Y, Kondo K, Levy JH. Morphological Changes in Blood Cells in a Rat Model of Heatstroke: A Pilot Study. J Clin Med. 2022 Aug 17;11(16):4821. 148. Iba T, Levi M, Thachil J, Levy JH. Disseminated Intravascular Coagulation: The Past, Present, and Future Considerations. Semin Thromb Hemost. 2022 Sep 13. doi: 10.1055/s-0042-1756300. 149. Tacquard C, Iba T, Levy JH. Perioperative Anaphylaxis. Anesthesiology. 2023 Jan 1;138(1):100-110. 【和文原著、総説、書籍】 1. 射場敏明: 虚血・再灌流後の微小循環障害における血管内皮機能調節の重要性. 日本薬理誌 131: 92-95, 2008. 2. 射場敏明: 2007年に発表されたエビデンスからみた重症セプシスの治療. 日本救急医会誌19: 91-98, 2008. 3. 射場敏明: DICのメカニズムとSurviving Sepsis Campaign Guidelines. 日本外科感染症学会雑誌 5: 323-328, 2008. 4. 射場敏明: SIRS-associated coagulopathy (SAC)の管理. 救急・集中治療 20: 1360-1364, 2008. 5. 射場敏明: 改訂版SSCGにおけるステロイドの使用. 医学の歩み 227: 893-896, 2008. 6. 射場敏明: 重症セプシス治療の歴史. 治療学 42: 123-127, 2008. 7. 射場敏明: 組織循環障害と白血球系細胞の役割およびこれを標的とした抗血栓治療. 医学の歩み 228: 1072-1076, 2009. 8. 射場敏明, 半井悦朗: 術後急性肺障害. 日本臨床別冊第4版: 282-285, 2009 9. 射場敏明, 真弓俊彦: 重症セプシス治療に関するエビデンスの不確実性. 日集中医誌 16: 255-262, 2009. 10. 射場敏明, 真弓俊彦, 小倉真治, 石倉宏恭, 小谷穣治, 松田直之, 横田裕行: 症セプシス治療に関する本邦の現状と国際的ガイドラインとの比較. 日救急医誌 20: 915-922, 2009. 11. 射場敏明, 川崎志保理: 白血球塞栓と末梢循環障害と血栓形成をみる.Vascular Medicine 6: 135-141, 2010. 12. 射場敏明, 川崎志保理: 感染症に起因するDICと凝固・線溶系分子マーカー. 日本外科感染症学会雑誌 7 137-142, 2010. 13. 射場敏明, 川崎志保理, 半井悦朗: DICと分子マーカー. ICUとCCU, 34: 583-589, 2010. 14. 射場敏明, 半井悦朗: ALI/ARDSに対するシベレスタット・ナトリウム療法とは. 救急・集中治療医学. 22: 1297-1300, 2010. 15. 射場敏明, 半井悦朗: セプティックdisseminated intravascular coagulation(DIC)に抗凝固療法は有効か？日集中医誌 17: 474-475, 2010. 16. 射場敏明, 真弓俊彦: セプシス治療の国際間比較. 日集中医誌 17: 545, 2010. 17. 射場敏明: 組織循環障害と白血球系細胞の役割およびこれを標的とした抗血栓治療. 医学の歩み別冊医歯薬出版: 130-134, 2010. 18. 射場敏明, 高山敏夫: 凝固線溶障害とDIC. 救急集中治療レビュー総合医学社: 351-355, 2010. 19. 射場敏明, 相原恒一郎: 凝固線溶障害とDIC. 救急・集中医学レビュー2011 島崎修次, 前川剛志監修, 341-345, 2011. 20. 田尻下敏弘, 相原恒一郎, 射場敏明: 出血性病態/血友病/HIT. 救急・集中治療 23(1, 2) 373-379, 2011. 21. 射場敏明, 齋藤大蔵: 敗血症性DIC に関する概念変化と診療の進歩. 日本救急医学会雑誌. 2011 22. 相原恒一郎, 射場敏明: 意識障害、高温障害を主訴に来院された83歳女性. 順天堂医学. 57: 84-86, 2011. 23. 射場敏明, 半井悦朗: 第三世代のDIC治療, アンチトロンビン. 臨床病理レビュー. 147: 167-170, 2011. 24. 射場敏明, 渡邉心: 欧州と日本の治療ガイドラインの相違. 臨床病理レビュー. 147: 209-212, 2011. 25. 射場敏明, 和田英夫. ICUにおける静脈血栓塞栓症予防 —とくに新世代の抗凝固薬について— 日本集中治療医学会雑誌 Vol. 19 (2012) No. 2:177-184 26. 射場敏明, 柳川洋一. SSCG 2012プレビュー日本救急医学会雑誌 Vol. 23 (2012) No. 7:329-330 27. 射場敏明, 柳川洋一. 最近のセプシストライアルから考えること日本救急医学会雑誌 Vol. 23 (2012) No. 6:282-283 28. 丸藤哲, 齋藤大蔵, 石倉宏恭, 上山昌史, 大友康裕, 織田成人, 久志本成樹, 丹正勝久, 真弓俊彦, 池田寿昭, 射場敏明, 江口豊, 岡本好司, 小倉裕司, 小関一英, 阪本雄一郎, 高山泰広, 遠藤重厚急性期DIC診断基準で診断された敗血症性DICに対するアンチトロンビンの効果日本救急医学会雑誌 Vol. 24 (2013) No. 2:105−115. 29. 射場敏明, 田部陽子. 敗血症性DICに対する抗凝固療法の実際. 日本検査血液学会雑誌 2015,16(2):115-20. 30. 射場敏明, 小倉裕司, 松田直之, 松嶋麻子, 澤村淳, 廣瀬智也, 坂本壮. 日本版重症敗血症診療ガイドライン2016作成に向けて　DIC対策:最近の話題と動向. ICUとCCU 2015;39(8):471-475. 31. 射場敏明. 動物DICモデルから学ぶDICの病態と治療. 血栓と循環 2015;23(2):84-88. 32. 射場敏明. 急性期DICの診療指針. 救急医学 2015;39(11):1544-1549. 33. 射場敏明. DIC対策. 救急・集中治療 sepsis・SIRS　2015,27(11):945-948. 34. 射場敏明. 敗血症性凝固異常における好中球細胞死の関与とDAMPs測定によるそのモニタリング. 体液・代謝管理 2015;31:35-40. 35. 射場敏明. 凝固線溶障害とDIC. 救急・集中治療レビュー 2016-17. 総合医学社 2016; 352-356. 36. 射場敏明. 好中球が関与する凝固の活性化と血栓形成. 血栓止血誌 27(3):308-315. 37. 射場敏明. グリコカリクスが関与する血管内腔の抗血栓性とそのその障害. 血栓止血誌 27(4):444-449. 38. 射場敏明, 渡邉心. 生体侵襲と細胞死. Thrombosis Medicine 6(3):5-10. 39. 射場敏明. DICの病態・診断トピックス. 救急医学 40:951-954. 40. 射場敏明. 国際血栓止血学会レポート (ISTH16). Thrombosis Medicine 6(3):66-68. 41. 射場敏明. アンチトロンビン濃縮製剤. 救急・集中治療アドバンス/重症患者における炎症と凝固・線溶系反応. 中山書店 2017; 352-356. 42. 射場敏明. 救急領域で用いられる薬. 疾病の回復を促進する薬. 放送大学教育振興会 2017; 4433: 210-224. 43. 射場敏明. 生体侵襲と好中球細胞死反応, そして細胞死による凝固・炎症の制御. 外科と代. 謝・栄養 2017 51(1): 1-7. 44. 射場敏明. アンチトロンビンによるDIC治療. Thrombosis Medicine 7(2):66-70. 45. 射場敏明. 深部静脈血栓症を簡便にスクリーニングするには？日本医事新報 2017;4859:58-59. 46. 射場敏明. 感染と細胞死. Coagulation & Inflammation 2017 3(1):19-25. 47. 射場敏明. 炎症と凝固の相互作用. 血液内科 2017;75(5)566-571. 48. 射場敏明. 凝固線溶異常の最新知見. ICUとCCU. 2018;42(1):17-23. 49. 射場敏明. 播種性血管内凝固症候群(DIC)の治療方針. 救急・集中治療最新ガイドライン2018-'19, pp52-54. 50. 射場敏明. 侵襲から臓器不全に至るメカニズム. 救急診療指針改定第5版救急医学会指導医・専門医 51. 射場敏明. 生体侵襲と血管内皮細胞機能. Thrombosis Medicine 8(1):11-16,2018. 52. 射場敏明. 欧米のガイドライン. 救急・集中治療vol 30 臨時増刊号2018 徹底ガイドDICのすべて 53. 射場敏明. アンチトロンビン製剤. 血栓止血誌 2019;30(1):228-232. 54. 射場敏明. グリコカリックス障害と臓器微小循環. 血栓止血誌 2019;30(5):726-732. 55. 射場敏明. 抗凝固薬とDIC: ガイドラインによる推奨度の相違. Thrombosis Medicine 2019;9(2):69-72. 56. 射場敏明. DIC診療の未来ーSCARLET has not gone with the wind. 医学と薬学 201976(7):995-998. 57. 射場敏明. DIC成立過程と基礎疾患. Thrombosis Medicine 2019;9(3):68-71. 58. 射場敏明. ISTH/DIC SSC 2019レポート. Thrombosis Medicine 2019;9(3):89-92. 59. 射場敏明, 相星淳一. 大量輸血に際してのmassive transfusion protocolと大量輸血にまつわる諸問題. 日外会誌 2020;121(4):454-457. 60. 射場敏明. 播種性血管内凝固症候群(DIC)の治療指針. 救急・集中治療最新ガイドライン2020-'21, pp53-55. 61. 射場敏明. DIC診断基準の国際間比較. Thrombosis Medicine 2019;9(4):77-80. 62. 射場敏明. 2020年を迎えて考えるDIC研究の展望. Thrombosis Medicine 2020;10(1):73-76. 63. 射場敏明. ビタミンC静注は急性呼吸窮迫症候群症候群合併セプシスの臓器障害を改善せず. MMJ 2020;16(2)41. 64. 射場敏明. 敗血症に起因する凝固障害と播種性血管内凝固(DIC). 麻酔 2020;69:740-748. 65. 射場敏明. COVID-19凝固異常症　抗凝固療法, 線溶・抗線溶療法. Thrombosis Medicine. 2021;11(3):200-206. 66. 射場敏明. COVID-19患者への早期の予防量hパリン投与死亡率を低下させる可能性. MMJ. 2021;17(5):139. 67. 射場敏明. 日本版敗血症診療ガイドライン2020の注目すべきトピックス: DIC診断と治療. ICUとCCU. 2021;45(9):579-587. 68. 射場敏明. 播種性血管内凝固症候群(DIC)の治療指針. 救急・集中治療最新ガイドライン2022-'23, pp55-58. (総合医学社) 69. 射場敏明. COVID-19ワクチンによるTTSの推定発生機序. Cardio-Coagulation. 2022;9(1):22-27. (メディカルレビュー社) 70. 射場敏明. 救急現場のDAMPs, PAMPsとRAMPs. Thrombosis Medicine. 2022;12(1):47-51. (先端医学社) 71. 射場敏明. COVID-19に対する抗血栓療法. Land-Mark in Thrombosis&Haemostasis. 2022;2:107-110. (メディカルレビュー社) 72. 射場敏明. 徹底ガイドDICのすべて2022-'23: 欧米のガイドライン. 救急・集中治療. 2022;34(2):704-709. (総合医学社) 73. 射場敏明. 徹底ガイドDICのすべて2022-'23: 日本版敗血症診療ガイドライン2020とDIC. 救急・集中治療. 2022;34(2):715-723. (総合医学社) 74. 射場敏明. 徹底ガイドDICのすべて2022-'23: アンチトロンビン. 救急・集中治療. 2022;34(2):862-867. (総合医学社) 75. 射場敏明. 血栓症と炎症：多臓器不全・多様な症状への進行機序. 医学のあゆみ. 2021;279(11):1115-1119.

研究テーマ

sepsis, coagulopathy, microcirculation, multiple organ failure, COVID-19, heatstroke

研究業績（論文）

【英文原著、総説】
1. Gando S, Saitoh D, Ogura H, Mayumi T, Koseki K, Ikeda T, Ishikura H, Iba T, Ueyama M, Eguchi Y, Ohtomo Y, Okamoto K, Kushimoto S, Endo S, Shimazaki S; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: Results of a multicenter, prospective survey. Crit Care Med 36: 145-150, 2008

2. Iba T, Miyasho T: Danaparoid sodium attenuates the increase in inflammatory cytokines and preserves organ function in endotoxemic rats. Crit Care 12: R86-91, 2008

3. Kushimoto S, Gando S, Saitoh D, Ogura H, Mayumi T, Koseki K, Ikeda T, Ishikura H, Iba T, Ueyama M, Eguchi Y, Otomo Y, Okamoto K, Endo S, Shimazaki S: Clinical course and outcome of disseminated intravascular coagulation diagnosed by Japanese Association for Acute Medicine criteria. Thromb Haemost 100: 1099-1105, 2008

4. Iba T, Ujike Y: Therapeutic approach to the septic organ dysfunction by anticoagulant therapy. Jpn J Thromb Hemost 19: 384-396, 2008

5. Gando S, Saitoh D, Ogura H, Mayumi T, Koseki K, Ikeda T, Ishikura H, Iba T, Ueyama M, Eguchi Y, Otomo Y, Okamoto K, Kushimoto S, Endo S, Shimazaki S; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. Disseminated intravascular coagulation (DIC) diagnosed based on the Japanese Association for Acute Medicine criteria is a dependent continuum to overt DIC in patients with sepsis. Thromb Res 123: 715-718, 2009

6. Iba T, Takayama T: Enoxaparin attenuates endothelial damage with less bleeding compared to unfractionated heparin in endotoxemic rats. Shock 32: 530-534, 2009

7. Iba T, Nakarai E, Takayama T, Nakajima K, Sasaoka T, Ohno Y: Combination effect of antithrombin and recombinant human soluble thrombomodulin in an LPS induced rat sepsis model. Critical Care 13: R203-209, 2009

8. Wada H, Asakura H, Okamoto K, Iba T, Uchiyama T, Kawasugi K, Koga S, Mayumi T, Koike K, Gando S, Kushimoto S, Seki Y, Madoiwa S, Maruyama I, Yoshioka A; Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res 125: 6-11, 2009

9. Iba T, Asakura H: Comparison between British and Japanese guidelines for the diagnosis and treatment of disseminated intravascular coagulation. Br J Haematol Epub 2010

10. Okamoto K, Wada H, Hatada T, Uchiyama T, Kawasugi K, Mayumi T, Gando S, Kushimoto S, Seki Y, Madoiwa S, Asakura H, Koga S, Iba T, Maruyama I; Japanese Society of Thrombosis Hemostasis/DIC subcommittee.Frequency and hemostatic abnormalities in pre-DIC patients. Thromb Res. 126: 74-78, 2010

11. Kawasaki S, Iba T: The current status of sepsis research in Japan and its international comparison. Juntendo Medical J 56: 334-338, 2010

12. Iba T, Okamoto K, Kawasaki S, Nakarai E, Miyasho T. Effect of hemoperfusion using polymyxin B-immobilized fibers on non-shock rat sepsis model. J Surg Res. 2011;171(2):755-61

13. Yanagawa Y, Tajima M, Ohara K, Aihara K, Matsuda S, Iba T. A case of cardiac arrest with ST elevation induced by contrast medium. Am J Emerg Med. 2012;30(9):2083.e3-4

14. Iba T; Japanese Association for Acute Medicine DIC Study Group. The meanings of DIC diagnostic criteria. Thromb Res. 2012;129(5):e269-70

15. Iba T, Okamoto K, Ohike T, Tajirika T, Aihara K, Watanabe S, Kayhanian H. Enoxaparin and fondaparinux attenuates endothelial damage in endotoxemic rats. J Trauma Acute Care Surg. 2012;72(1):177-82

16. Iba T, Aihara K, Kawasaki S, Yanagawa Y, Niwa K, Ohsaka A. Formation of the venous thrombus after venous occlusion in the experimental mouse model of metabolic syndrome. Thromb Res. 2012;129(5):e246-50

17. Iba T, Saito D, Wada H, Asakura H. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a prospective multicenter survey. Thromb Res. 2012;130(3):e129-33

18. Yanagawa Y, Hirano Y, Kato H, Iba T. The absence of typical pneumonia symptoms in a patient with rheumatoid arthritis during tocilizumab and steroid treatment. BMJ Case Rep. 2012 May 23

19. Iba T, Aihara K, Watanabe S, Yanagawa Y, Takemoto M, Yamada A, Yang D. Recombinant thrombomodulin improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat LPS model. Thromb Res. 2013;131(4):295-9

20. Iba T, Nagaoka I, Boulat M. The anticoagulant therapy for sepsis-associated disseminated intravascular coagulation. Thromb Res. 2013;131(5):383-9.

21. Iba T, Aihara K, Watanabe S, Yanagawa Y, Yamada A, Koichiro N, Ohsaka A. Factor Xa inhibitor attenuates leukocyte adhesion and thrombus formation in an experimental mouse model of the metabolic syndrome. Cardiovasc Ther. 2013 May 1

22. Yanagawa Y, Yoshihara T, Kato H, Iba T, Tanaka H. Significance of urinary incontinence, age, and consciousness level on arrival among patients with stroke. J Emerg Trauma Shock. 2013;6(2):83-6

23. Iba T, Aihara K, Watanabe S, Yanagawa Y, Takemoto M, Yamada A, Yang D. Recombinant thrombomodulin improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat LPS model. Thromb Res. 2013;131(4):295-9.

24. Iba T, Aihara K, Watanabe S, Yanagawa Y, Yamada A, Koichiro N, Ohsaka A. Factor Xa inhibitor attenuates leukocyte adhesion and thrombus formation in an experimental mouse model of the metabolic syndrome. Cardiovasc Ther. 2013;31(5):280-284.

25. Yanagawa Y, Yoshihara T, Kato H, Iba T, Tanaka H. Significance of urinary incontinence, age, and consciousness level on arrival among patients with stroke. J Emerg Trauma Shock. 2013;6(2):83-6.

26. Iba T, Miki T, Hashiguchi N, Yamada A, Nagaoka I: Combination of antithrombin and recombinant thrombomodulin attenuates leukocyte-endothelial interaction and suppresses the increase of intrinsic DAMPs in endotoxemic rats. J Surg Res 2014 187(2):581-586.

27. Gando S, Saitoh D, Ishikura H, Ueyama M, Otomo Y, Oda S, Kushimoto S, Tanjoh K, Mayumi T, Ikeda T, Iba T, Eguchi Y, Okamoto K, Ogura H, Koseki K, Sakamoto Y, Takayama Y, Shirai K, Takasu O, Inoue Y, Mashiko K, Tsubota T, Endo S: A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care 2013 ;17(6):R297

28. Iba T, Nagaoka I, Yamada A, Nagayama M, Miki T: Effect of Hemoperfusion Using Polymyxin B-immobilized Fibers on Acute Lung Injury in a Rat Sepsis Model. Int J Med Sci 2014;11(3):255-261.

29. Hu Z, Murakami T, Suzuki K, Tamura H, Kuwahara-Arai K, Iba T, Nagaoka I. Antimicrobial Cathelicidin Peptide LL-37 Inhibits the LPS/ATP-Induced Pyroptosis of Macrophages by Dual Mechanism. PLoS One 2014;9(1):e85765

30. Iba T, Aihara K, Yamada A, Nagayama M, Tabe Y, Ohsaka A. Rivaroxaban attenuates leukocyte adhesion in the microvasculature and thrombus formation in an experimental mouse model of type 2 diabetes mellitus. Thromb Res 2014;133(2):276-280.

31. Iba T, Miki T, Hashiguchi N, Tabe Y, Nagaoka I. Combination of antithrombin and recombinant thrombomodulin modulates neutorophil cell-death and decreases circulating DAMPs levels in endotoxemic rats. Thromb Res 2014;134(1):169-173.

32. Iba T, Saitoh D, Wada H, Asakura H: Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey. Critical Care 2014;18(5):497.

33. Iba T, Saitoh D, Gando S, Thachil J: The usefulness of antithrombin activity monitoring during antithrombin supplementation in patients with sepsis-associated disseminated intravascular coagulation. Thromb Res 2015;135(5):897-901.

34. Iba T, Nagakari K: The effect of plasma-derived activated protein C on leukocyte cell-death and vascular endothelial damage. Thromb Res 2015;135(5):963-9.

35. Miki T, Iba. Kinetics of Circulating Damage-Associated Molecular Patterns in Sepsis.J Immunol Res 2015;2015:424575. doi: 10.1155/2015/424575.

36. Yuri M, Tabe Y, Tsuchiya K, Sadatsuki R, Aoki J, Horii T, Iba T, Ohsaka A.Evaluation of Factor Xa-Specific Chromogenic Substrate Assays and the Determination of Pharmacokinetics of Fondaparinux. Clin Appl Thromb Hemost. Jul 15. pii: 1076029615595878.

37. Iba T, Hashiguchi N, Nagaoka I, Tabe Y, Kadota K, Sato K. Heparins attenuated histone-mediated cytotoxicity in vitro and improved the survival in a rat model of histone-induced organ dysfunction. Intensive Care Med Exp. 2015;3(1):36.

38. Iba T, Ito T, Maruyama I, Jilma B, Brenner T, Müller MCA, Juffermans NP, Thachil J. Potential diagnostic markers for disseminated intravascular coagulation of sepsis. Blood Reviews 2016;30(2):149-155.

39. Iba T, Thachil J. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a Japanese perspective. International Journal of hematology 2016;103(3):253-61.

40. Liaw P, Ito T, Iba T, Thachil J, Zeerleder S. DAMP and DIC: the role of extracellular DNA and DNA-binding proteins in the pathogenesis of DIC. Blood Reviews 2015 Dec 31. pii: S0268-960X(15)00097-1. doi: 10.1016/j.blre.2015.12.004.

41. Iba T, Hamakubo T, Nagaoka I, Sato K. Physiological levels of pentraxin 3 and albumin attenuate vascular endothelial cell damage induced by histone H3 in vitro. Microcirculation 2016;23(3):240-247.

42. Nagakari K. Iba T, Emmi M. Prothrombin time tests for the monitoring of direct oral anticoagulants and their evaluation as indicators of the reversal effect. Clin Appl Thromb Hemost 2016 Mar 16.

43. Iba T, Emmi M, Hiki M, Nagayama M, Aihara K, Tabe Y, Yuri M, Ohsaka A. Comparison of prothrombin tests used in the monitoring of edoxaban and their evaluation as indicators of reversal effect. Int J Hematol 2016;103(6): 665-672.

44. Iba T, Saitoh D, Gando S, Ikeda T, Anan H, Oda S, Kitamura N, Mori S, Kotan J, Kuroda Y. Efficacy and bleeding risk of antithrombin supplementation in patients with septic disseminated intravascular coagulation: A third survey. Clin Appl Thromb Hemost 2016 pii: 1076029616648405.

45. Iba T, Gando S, Saitoh D, Wada H, Di Nisio M, Thachil J. Antithrombin supplementation and risk of bleeding in patients with sepsis-associated disseminated intravascular coagulation. Thromb Res 2016;145:46-50.

46. Iba T, Di Nisio M, Thachi J, Wada H, Asakura H, Sato K, Kitamura N, Saitoh D. Revision of the Japanese Association for Acute Medicine (JAAM)-disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity. Crit Care 2016;20:287.

47. Iba T. Glycocalyx regulates the intravascular hemostasis. Juntendo Medical J 2016, 62(4):330-335.

48. Iba T, Thachil J. Is antithrombin III for sepsis-associated disseminated intravascular coagulation really ineffective? Intensive Care Med 2016　42(7):1193-1194.

49. Iba T, Thachil J. Is protein C zymogen really ineffective for ALL cases of sepsis including septic DIC? Intensive Care Med 2016　43(1):152-153.

50. Iba T. Bleeding complications of anticoagulant therapy in sepsis-induced disseminated intravascular coagulation. Crit Care 2016;20:307.

51. Hu Z, Murakami T, Tamura H, Reich J, Kuwahara-Arai K, Iba T, Tabe Y, Nagaoka I. Neutrophil extracellular traps induce IL-1β production by macrophages in combination with lipopolysaccharide. Int J Mol Med. 2017;39(3):549-558.

52. Takehara K, Murakami T, Kuwahara-Arai K, Iba T, Nagaoka I, Sakamoto K. Evaluation of the effect of recombinant thrombomodulin on a lipopolysaccharide‑induced murine sepsis model. Experimental and Therapeutic Medicine. 2017;13(6):2969-2974.

53. Iba T, Sasaki T, Ohno T, Sato K, Nagaoka I, Thachil J. β-Antithrombin attenuates vascular endothelial cell damage induced by histone more efficiently than α-antithrombin. Thromb Haemost Open 2017

54. Iba T, Di Nisio M, Thachil J, Wada H, Asakura H, Sato K, Saitoh D. A proposal of the modification of Japanese Society on Thrombosis and Hemostasis (JSTH)-disseminated intravascular coagulation (DIC) diagnostic criteria for sepsis-associated DIC. Clin Appl Thromb Hemost 2017doi: 10.1177/1076029617720069.

55. Iba T, Di Nisio M, Levy J, Kitamura N, Thachil J. New Criteria for Sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open 2017;7:e017046.

56. Hosoda H, Nakamura K, Hu Z, Tamura H, Reich J, Kuwahara-Arai K, Iba T, Tabe Y, Nagaoaka I. Mol Med Rep. 2017 Aug 17. doi: 10.3892/mmr.2017.7267.

57. Iba T, Hagiwara A, Saitoh D, Anan H, Ueki Y, Sato K, Gando S. Effects of combination therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation. Annals of Intensive Care 2017, 7:110.

58. Iba T, Levy, J. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost 2017, DOI:10.1111/jth.13911

59. Iba T, Thachil, J. Clinical significance of measuring plasminogen activator inhibitor-1 in sepsis. J Intensive Care 2017;5:56.

60. Thachil J, Iba T. The application of anticoagulant therapy to sepsis. J Intensive Care. 2017;5:32.

61. Iba T, Fowler L. Is polymyxin B-immobilized fiber column ineffective for septic shock? A discussion on the press release for EUPHRATES trial. J Intensive Care 2017;5:40.

62. Iba T, Hirota T, Sato K, Nagaoka I. Protective effect of a newly developed fucose-deficient recombinant antithrombin against histone-induced endothelial damage. Int J Hematol 2018;107(5):528-534.

63. Iba T, Arakawa M, Levy JH, Yamakawa K, Koami H, Hifumi T, Sato K. Sepsis-Induced Coagulopathy and Japanese Association for Acute Medicine DIC in Coagulopathic Patients with Decreased Antithrombin and Treated by Antithrombin. Clin Appl Thromb Hemost. 2018;24(7):1020-1026.

64. Iba T, Arakawa M, Di Nisio M, Gando S, Anan H, Sato K, Ueki Y, Levy JH, Thachil J. Newly Proposed Sepsis-Induced Coagulopathy Precedes International Society on Thrombosis and Haemostasis Overt-Disseminated Intravascular Coagulation and Predicts High Mortality. J Intensive Care Med. 2018 Jan 1:885066618773679.

65. Suzuki K, Wada H, Imai H, Iba T. A reevaluation of the D-dimer cut-off value for making a diagnosis using the ISTH overt-DIC diagnostic criteria: communication from the SSC of the ISTH. J Thromb Haemost

66. Nishida O, Ogura H, Egi M, Fujishima S, Hayashi Y, Iba T, et al. The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016). Acute Med Surg. 2018;5(1):3-89.

67. Wada H, Matsumoto T, Suzuki K, Imai H, Katayama N, Iba T, Matsumoto M. Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thromb J. 2018;11;16:14.

68. Iba T, Arakawa M, Ohchi Y, Arai T, Sato K, Wada H, Levy JH. Prediction of early death in patients with sepsis-associated coagulation disorder treated with antithrombin supplementation. Clin Appl Thromb Hemost. 2018;1076029618797474. doi: 10.1177/1076029618797474

69. Iba T, Levy JH, Hirota T, Hiki M, Sato K, Murakami T, Nagaoka I. Protection of the endothelial glycocalyx by antithrombin in an endotoxin-induced rat model of sepsis. Thromb Res. 2018; 171:1-6.

70. Iba T. Tanaka H. Oh, how hard it is to open the gate of sepsis trial: lessons from SCARLET. Acute Med Surg. 2018;6(1):3-4.

71. Demma LJ, Faraoni D, Winkler AM, Iba T, Levy JH. Predicting mortality in patients with disseminated intravascular coagulation after cardiopulmonary bypass surgery by utilizing two scoring systems. Blood Coagul Fibrinolysis. 2018;30(1):11-16.

72. Iba T, Ogura H. Role of extracellular vesicles in the development of sepsis-induced coagulopathy. J Intensive Care. 2018;6(1):68.

73. Iba T, Levy JH. Derangement of the endothelial glycocalyx in sepsis. J Thromb Haemost. 2018, 17(2):283-294.

74. Iba T, Levy JH, Wada H, Thachil J, Warkentin T, Levi M; Subcommittee on Disseminated Intravascular Coagulation. Differential diagnoses for sepsis‐induced disseminated intravascular coagulation: communication from the SSC of the ISTH. J Thromb Haemost. 2018;17(2):415-419.

75. Iba T, Arakawa M, Mochizuki K, Nishida O, Wada H, Levy JH. Usefulness of Measuring Changes in SOFA Score for the Prediction of 28-Day Mortality in Patients With Sepsis-Associated Disseminated Intravascular Coagulation. Clin Appl Thromb Hemost. 2019;25:1076029618824044.

76. Fukushima Y, Yamada A, Imoto N, Iba T. Does TeamSTEPPS affect psychological status? Int J Health Care Qual Assur. 2019;32(1):11-20.

77. Iba T, Levy JH, Thachil J, Wada H, Levi M; Scientific and Standardization Committee on DIC of the International Society on Thrombosis and Haemostasis. The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases. Thromb Res. 2019;179:11-14.

78. Iba T, Levy JH, Yamakawa K, Thachil J, Warkentin TE, Levi M; Scientific and Standardization Committee on DIC of the International Society on Thrombosis and Haemostasis. Proposal of a two-step process for the diagnosis of sepsis-induced disseminated intravascular coagulation. J Thromb Haemost. 2019;17(8):1265-1268.

79. Iba T, Levy JH, Raj A, Warkentin TE. Advance in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. J Clin Med. 2019;8(5). pii: E728.

80. Iba T, Klein DJ. The wind changed direction and the big river still flows: from EUPHRATES to TIGRIS. J Intensive Care. 2019;7:31.

81. Iba T, Watanabe E, Umemura Y, Wada T, Hayashida K, Kushimoto S; Japanese Surviving Sepsis Campaign Guideline Working Group for disseminated intravascular coagulation, Wada H. Sepsis-associated disseminated intravascular coagulation and its differential diagnoses. J Intensive Care. 2019;7:32.

82. Rabinovich A, Abdul-Kadir R, Thachil J, Iba T, Othman M, Erez O. DIC in obstetrics: Diagnostic score, highlights in management, and international registry-communication from the DIC and Women's Health SSCs of the International Society of Thrombosis and Haemostasis. J Thromb Haemost. 2019;17(9):1562-1566.

83. Suzuki K, Wada H, Matsumoto T, Ikejiri M, Ohishi K, Yamashita Y, Imai H, Iba T, Katayama N. Usefulness of the APTT waveform for the diagnosis of DIC and prediction of the outcome or bleeding risk. Thromb J. 2019;17:12.

84. Iba T, Umemura Y, Watanabe E, Wada T, Hayashida K, Kushimoto S; Japanese Surviving Sepsis Campaign Guideline Working Group for disseminated intravascular coagulation. Diagnosis of sepsis-induced disseminated intravascular coagulation and coagulopathy. Acute Med Surg. 2019;6(3):223-232.

85. Levy JH, Ghadimi K, Faraoni D, van Diepen S, Levy B, Hotchkiss R, Connors JM, Iba T, Warkentin TE. Ischemic limb necrosis in septic shock: What is the role of high-dose vasopressor therapy? J Thromb Haemost. 2019;17(11):1973-1978.

86. Iba T, Levy JH, Warkentin TE, Thachil J, van der Poll T, Levi M; Scientific and Standardization Committee on DIC, and the Scientific and Standardization Committee on Perioperative and Critical Care of the International Society on Thrombosis and Haemostasis. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989-1994.

87. Ito T, Thachil J, Asakura H, Levy JH, Iba T. Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential. Crit Care. 2019;23(1):280.

88. Aoki J, Sakamoto K, Takahashi R, Niwa K, Ishiyama S, Sugimoto K, Kamiyama H, Takahashi M, Kojima Y, Goto M, Tomiki Y, Iba T. Current status of venous thromboembolism development during the perioperative period for colorectal cancer, its prevention with enoxaparin, and monitoring methods. Ther Clin Risk Manag. 2019;15:791-802.

89. Iba T, Levi M, Levy JH. Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Semin Thromb Hemost. 2019 Aug 23. doi: 10.1055/s-0039-1694995.

90. Yamakawa K, Levy JH, Iba T. Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis. Crit Care. 2019;5;23(1):302.

91. Hayashi N, Yamaguchi S, Rodenburg F, Ying Wong S, Ujimoto K, Miki T, Iba T. Multiple biomarkers of sepsis identified by novel time-lapse proteomics of patient serum. PLoS One. 2019;14(9):e0222403.

92. Iba T, Levy JH. Sepsis-induced Coagulopathy and Disseminated Intravascular Coagulation. Anesthesiology. 2020;132(5):1238-1245.

93. Moore HB, Gando S, Iba T, Kim PY, Yeh CH, Brohi K, Hunt BJ, Levy JH, Draxler DF, Stanworth S, Görlinger K, Neal MD, Schreiber MA, Barrett CD, Medcalf RL, Moore EE, Mutch NJ, Thachil J, Urano T, Thomas S, Scărlătescu E, Walsh M; Subcommittees on Fibrinolysis, Disseminated Intravascular Coagulation, and Perioperative and Critical Care Thrombosis and Hemostasis. Defining trauma-induced coagulopathy with respect to future implications for patient management: Communication from the SSC of the ISTH. J Thromb Haemost. 2020;18(3):740-747.

94. Hirota T, Levy JH, Iba T. The influence of hyperglycemia on neutrophil extracellular trap formation and endothelial glycocalyx damage in a mouse model of type 2 diabetes. Microcirculation. 2020;27(5):e12617.

95. Valeriani E, Squizzato A, Gallo A, Porreca E, Vincent JL, Iba T, Hagiwara A, Di Nisio M. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy: a systematic review and meta-analysis. J Thromb Haemost. 2020;18(7):1618-1625.

96. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. DOACs and 'newer' haemophilia therapies in COVID-19. J Thromb Haemost. 2020;18(7):1795-1796.

97. Thachil J, Tang N, Gando S, Falanga A, Levi M, Clark C, Iba T. Laboratory haemostasis monitoring in COVID-19. J Thromb Haemost. 2020;18(8):2058-2060.

98. Thachil J, Tang N, Gando S, Falanga A, Levi M, Clark C, Iba T, Cattaneo M. Type and dose of heparin in COVID-19. J Thromb Haemost. 2020;18(8):2063-2064.

99. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-1026.

100. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;S2352-3026(20)30145-9.

101. Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T, Levi M, Samama CM, Thachil J, Giannis D, Douketis JD. Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19. J Thromb Haemost. 2020;18(8):1859-1865.

102. Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of Coronavirus Disease 2019. Crit Care Med. 2020;48(9):1358-1364.

103. Iba T, Levy JH, Warkentin TE, Thachil J, van der Poll T, Levi M. RE: The prothrombin time ratio is not a more effective marker for evaluating sepsis-induced coagulopathy than fibrin-related markers: Response to the Letter-to-the-Editor by Dr Wada. J Thromb Haemost. 2020;18(6):1507-1509.

104. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24(1):360.

105. Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. J Thromb Haemost. 2020;18(9):2103-2109.

106. Kumagai Y, Murakami T, Kuwahara-Arai, Iba T, Reich J, Nagaoka I. Antimicrobial peptide LL-37 ameliorates a murine sepsis model via the induction of microvesicle release from neutrophils. Innate Immun. 2020 Jun 29:1753425920936754.

107. Rabinovich A, Abdul-Kadir R, Thachil J, Iba T, Othman M, Erez O. Reply to "Errors in the diagnosis for DIC due to a statistical misunderstanding". J Thromb Haemost. 2020;18(7):1792-1793.

108. Kadir RA, Kobayashi T, Iba T, Erez O, Thachil J, Kazi S, Malinowski AK, Othman M. COVID-19 Coagulopathy in Pregnancy: Critical Review, Preliminary Recommendations and ISTH Registry - Communication from the ISTH SSC for Women's Health. J Thromb Haemost. 2020 Aug 26. doi: 10.1111/jth.15072.

109. Thachil J, Juffermans NP, Ranucci M, Connors JM, Warkentin TE, Ortel TL, Levi M, Iba T, Levy JH. ISTH DIC subcommittee communication on anticoagulation in COVID-19. J Thromb Haemost. 2020;18(9):2138-2144.

110. Squizzato A, Gallo A, Levi M, Iba T, Levy JH, Erez O, Ten Cate H, Solh Z, Gando S, Vicente V, Di Nisio M. Underlying disorders of disseminated intravascular coagulation: Communication from the ISTH SSC Subcommittees on Disseminated Intravascular Coagulation and Perioperative and Critical Care Thrombosis and Hemostasis. J Thromb Haemost. 2020;18(9):2400-2407.

111. Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm Res. 2020 Dec;69(12):1181-1189.

112. Iba T, Levy JH, Levi M, Connors JM, Thachil J. The authors reply. Crit Care Med. 2020 Oct;48(10):e989-e990.

113. Iba T, Levy JH, Levi M, Connors JM, Thachil J. The authors reply. Crit Care Med. 2020 Nov;48(11):e1160-e1161.

114. Iba T. Thrombin-Antithrombin System. H.B. Moore, et al. (eds.) Trauma-Induced Coagulopathy, Springer Nature Switzerland AG2021, pp43-51.

115. Levy JH, Iba T, Connors JM. Vascular injury in acute infections and COVID-19: everything old is new again. Trends Cardiovasc Med. 2020 Oct 28:S1050-1738(20)30134-1.

116.　Levy JH, Iba T, Connors JM. Editorial commentary: Vascular injury in acute infections and COVID-19: everything old is new again. Trends Cardiovasc Med. 2021 Jan;31(1):6-7.

117.　Iba T, Levy JH, Aihara K, Kadota K, Tanaka H, Sato K, Nagaoka I. Newly Developed Recombinant Antithrombin Protects the Endothelial Glycocalyx in an Endotoxin-Induced Rat Model of Sepsis. Int J Mol Sci. 2020 Dec 26;22(1):176.

118.　Iba T, Connors JM, Nagaoka I, Levy JH. Recent advances in the research and management of sepsis-associated DIC. Int J Hematol. 2021 Jan;113(1):24-33.

119.　Iba T, Warkentin TE, Thachil J, Levi M, Levy JH. Proposal of the Definition for COVID-19-Associated Coagulopathy. J Clin Med. 2021 Jan 7;10(2):E191.

120.　Iba T, Connors JM, Spyropoulos AC, Wada H, Levy JH. Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered? Int J Hematol. 2021 Jan 20. doi: 10.1007/s12185-021-03078-x.

121. Connors JM, Iba T, Gandhi RT. Thrombosis and COVID-19: Controversies and (Tentative) Conclusions. Clin Infect Dis. 2021 Feb 4:ciab096. doi: 10.1093/cid/ciab096.

122. Kawasugi K, Wada H, Honda G, Kawano N, Uchiyama T, Madoiwa S, Takezako N, Suzuki K, Seki Y, Ikezoe T, Iba T, Okamoto K. Hypofibrinogenemia is associated with a high degree of risk in infectious diseases: a post-hoc analysis of post-marketing surveillance of patients with disseminated intravascular coagulation treated with thrombomodulin alfa. Thromb J. 2021 Feb 25;19(1):12.

123. Hayashi N, Sawada Y, Ujimoto K, Yamaguchi S, Sato Y, Miki T, Nakada, Iba T. Diagnosis of Sepsis by AI-Aided Proteomics Using 2D Electrophoresis Images of Patient Serum Incorporating Transfer Learning for Deep Neural Networks. Applied Sciences. 2021, 11(4), 1967.

124. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. Managing thrombosis and cardiovascular complications of COVID-19: Answering the questions in COVID-19-associated coagulopathy. Expert Rev Respir Med. 2021 Aug;15(8):1003-1011.

125. Iba T, Warkentin TE, Connors JM, Levy JH. Therapeutic strategies in patients with coagulopathy and disseminated intravascular coagulation: awareness of the phase-dependent characteristics. Minerva Med. 2021 Mar 12. doi: 10.23736/S0026-4806.21.07469-3.

126. Levy JH, Iba T, Gardiner EE. Endothelial Injury in COVID-19 and Acute Infections: Putting the Pieces of the Puzzle Together. Arterioscler Thromb Vasc Biol. 2021 Apr 1:ATVBAHA121316101. doi: 10.1161/ATVBAHA.121.316101.

127. Arakawa M, Levy JH, Fujimori K, Kondo K, Iba T. A new SOFA score calculation to improve the predictive performance for mortality in sepsis-associated disseminated intravascular coagulopathy patients. J Crit Care. 2021 Mar 22;64:108-113.

128. Mitaka C, Kusao M, Kawagoe I, Satoh D, Iba T, Ronco C. Impact of Extended Duration of Polymyxin B-Immobilized Fiber Column Direct Hemoperfusion on Hemodynamics, Vasoactive Substance Requirement, and Pulmonary Oxygenation in Patients with Sepsis: An Observational Study. Blood Purif. 2021 Apr 28:1-8.

129. Yamamoto A, Wada H, Ichkawa Y, Tanaka M, Tashiro H, Shiraki K, Shimpo H, Yamashita Y, Mastumoto T, Shimaoka M, Iba T, Suzuki-Inoue K. Soluble C-Type Lectin-Like Receptor 2 Is a Biomarker for Disseminated Intravascular Coagulation. J Clin Med. 2021 Jun 28;10(13):2860.

130. Iba T, Levy JH, Warkentin TE. Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia. Crit Care Med. 2021 Jul 13. doi: 10.1097/CCM.0000000000005211.

131. Levy JH, Iba T, Olson LB, Corey KM, Ghadimi K, Connors JM. COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations. Int J Lab Hematol. 2021 Jul;43 Suppl 1:29-35.

132. Iba T, Levy JH, Levi M. Viral-induced inflammatory coagulation disorders: Preparing for another epidemic. Thromb Haemost. 2021 Jul 30. doi: 10.1055/a-1562-7599.

133. Iba T, Umemura Y, Wada H, Levy H. The Roles of Coagulation Disorder and Microthrombosis in Sepsis: Pathophysiology, Diagnosis, and Treatment. Arch Med Res. 2021 Jul 31:S0188-4409(21)00162-4.

134. Egi M, Ogura H, Yatabe T, Atagi K, Inoue S, Iba T, et al. The Japanese Clini20.cal Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J-SSCG 2020). J Intensive Care. 2021 Aug 25;9(1):53.

135. Iba T, Levy JH. The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia. Trends Cardiovasc Med. 2021 Aug 26:S1050-1738(21)00096-7. doi: 10.1016/j.tcm.2021.08.012.

136. Mitaka C, Iba T, Ronco C. Polymyxin B-Immobilized Fiber Column Direct Hemoperfusion for Micro-Preemie Infants with Septic Shock. Is Extended Duration Better than Early Start? Comment to the Letter to the Editor of Nishizaki and Colleagues. Blood Purif. 2021 Sep 16:1-2. doi: 10.1159/000518904.

137. Iba T, Levy JH, Warkentin TE. Pitfalls in Diagnosing Vaccine-Induced Immune Thrombotic Thrombocytopenia. Crit Care Med. 2021 Sep 24. doi: 10.1097/CCM.0000000000005371.

138. Iba T, Nishida O, Levy JH, Levi M. Nevertheless, the importance of coagulation abnormalities should be emphasized in international sepsis guidelines. J Intensive Care. 2022 Jan 21;10(1):4.

139. Iba T, Connors JM, Levi M, Levy JH. Heatstroke-induced coagulopathy: Biomarkers, mechanistic insights, and patient management. EClinicalMedicine. 2022 DOI:https://doi.org/10.1016/j.eclinm.2022.101276

140. Iba T, Levy JH. Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination. Trends Cardiovasc Med. 2022 Feb 22:S1050-1738(22)00038-X.

141. Wada H, Ichikawa Y, Ezaki M, Yamamoto A, Tomida M, Yoshida M, Fukui S, Moritani I, Shiraki K, Shimaoka M, Iba T, Suzuki-Inoue K, Shimpo H. Elevated Plasma Soluble C-Type Lectin-like Receptor 2 Is Associated with the Worsening of Coronavirus Disease 2019. J Clin Med. 2022 Feb 14;11(4):985.

142. Iba T, Wada H, Levy JH. Platelet Activation and Thrombosis in COVID-19. Semin Thromb Hemost. 2022 Jun 23.

143. Connors JM, Iba T. Vaccine-induced immune thrombotic thrombocytopenia and patients with cancer Thrombosis Research 2022 May; 213(Suppl 1):S77-S83.

144. Schulman S, Sholzberg M, Spyropoulos AC, Zarychanski R, Resnick HE, Bradbury CA, Broxmeyer L, Connors JM, Falanga A, Iba T, Kaatz S, Levy JH, Middeldorp S, Minichiello T, Ramacciotti E, Samama CM, Thachil J; International Society on Thrombosis and Haemostasis. ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost. 2022 Oct;20(10):2214-2225.

145. Iba T, Levi M, Levy JH. Intracellular communication and immunothrombosis in sepsis. J Thromb Haemost. 2022 Aug 17. doi: 10.1111/jth.15852.

146. Iba T, Helms J, Levi M, Levy JH. The role of platelets in heat-related illness and heat-induced coagulopathy. Thromb Res. 2022 Aug 17:S0049-3848(22)00342-5.

147. Iba T, Sawada T, Kondo Y, Kondo K, Levy JH. Morphological Changes in Blood Cells in a Rat Model of Heatstroke: A Pilot Study. J Clin Med. 2022 Aug 17;11(16):4821.

148. Iba T, Levi M, Thachil J, Levy JH. Disseminated Intravascular Coagulation: The Past, Present, and Future Considerations. Semin Thromb Hemost. 2022 Sep 13. doi: 10.1055/s-0042-1756300.

149. Tacquard C, Iba T, Levy JH. Perioperative Anaphylaxis. Anesthesiology. 2023 Jan 1;138(1):100-110.

【和文原著、総説、書籍】
1. 射場敏明: 虚血・再灌流後の微小循環障害における血管内皮機能調節の重要性. 日本薬理誌 131: 92-95, 2008.

2. 射場敏明: 2007年に発表されたエビデンスからみた重症セプシスの治療. 日本救急医会誌19: 91-98, 2008.

3. 射場敏明: DICのメカニズムとSurviving Sepsis Campaign Guidelines. 日本外科感染症学会雑誌 5: 323-328, 2008.

4. 射場敏明: SIRS-associated coagulopathy (SAC)の管理. 救急・集中治療 20: 1360-1364, 2008.

5. 射場敏明: 改訂版SSCGにおけるステロイドの使用. 医学の歩み 227: 893-896, 2008.

6. 射場敏明: 重症セプシス治療の歴史. 治療学 42: 123-127, 2008.

7. 射場敏明: 組織循環障害と白血球系細胞の役割およびこれを標的とした抗血栓治療. 医学の歩み 228: 1072-1076, 2009.

8. 射場敏明, 半井悦朗: 術後急性肺障害. 日本臨床別冊第4版: 282-285, 2009

9. 射場敏明, 真弓俊彦: 重症セプシス治療に関するエビデンスの不確実性. 日集中医誌 16: 255-262, 2009.

10. 射場敏明, 真弓俊彦, 小倉真治, 石倉宏恭, 小谷穣治, 松田直之, 横田裕行: 症セプシス治療に関する本邦の現状と国際的ガイドラインとの比較. 日救急医誌 20: 915-922, 2009.

11. 射場敏明, 川崎志保理: 白血球塞栓と末梢循環障害と血栓形成をみる.Vascular Medicine 6: 135-141, 2010.

12. 射場敏明, 川崎志保理: 感染症に起因するDICと凝固・線溶系分子マーカー. 日本外科感染症学会雑誌 7 137-142, 2010.

13. 射場敏明, 川崎志保理, 半井悦朗: DICと分子マーカー. ICUとCCU, 34: 583-589, 2010.

14. 射場敏明, 半井悦朗: ALI/ARDSに対するシベレスタット・ナトリウム療法とは. 救急・集中治療医学. 22: 1297-1300, 2010.

15. 射場敏明, 半井悦朗: セプティックdisseminated intravascular coagulation(DIC)に抗凝固療法は有効か？日集中医誌 17: 474-475, 2010.

16. 射場敏明, 真弓俊彦: セプシス治療の国際間比較. 日集中医誌 17: 545, 2010.

17. 射場敏明: 組織循環障害と白血球系細胞の役割およびこれを標的とした抗血栓治療. 医学の歩み別冊医歯薬出版: 130-134, 2010.

18. 射場敏明, 高山敏夫: 凝固線溶障害とDIC. 救急集中治療レビュー総合医学社: 351-355, 2010.

19. 射場敏明, 相原恒一郎: 凝固線溶障害とDIC. 救急・集中医学レビュー2011 島崎修次, 前川剛志監修, 341-345, 2011.

20. 田尻下敏弘, 相原恒一郎, 射場敏明: 出血性病態/血友病/HIT. 救急・集中治療 23(1, 2) 373-379, 2011.

21. 射場敏明, 齋藤大蔵: 敗血症性DIC に関する概念変化と診療の進歩. 日本救急医学会雑誌. 2011

22. 相原恒一郎, 射場敏明: 意識障害、高温障害を主訴に来院された83歳女性. 順天堂医学. 57: 84-86, 2011.

23. 射場敏明, 半井悦朗: 第三世代のDIC治療, アンチトロンビン. 臨床病理レビュー. 147: 167-170, 2011.

24. 射場敏明, 渡邉心: 欧州と日本の治療ガイドラインの相違. 臨床病理レビュー. 147: 209-212, 2011.

25. 射場敏明, 和田英夫. ICUにおける静脈血栓塞栓症予防 —とくに新世代の抗凝固薬について— 日本集中治療医学会雑誌 Vol. 19 (2012) No. 2:177-184

26. 射場敏明, 柳川洋一. SSCG 2012プレビュー日本救急医学会雑誌 Vol. 23 (2012) No. 7:329-330

27. 射場敏明, 柳川洋一. 最近のセプシストライアルから考えること日本救急医学会雑誌 Vol.
23 (2012) No. 6:282-283

28. 丸藤哲, 齋藤大蔵, 石倉宏恭, 上山昌史, 大友康裕, 織田成人, 久志本成樹, 丹正勝久, 真弓俊彦, 池田寿昭, 射場敏明, 江口豊, 岡本好司, 小倉裕司, 小関一英, 阪本雄一郎, 高山泰広, 遠藤重厚急性期DIC診断基準で診断された敗血症性DICに対するアンチトロンビンの効果日本救急医学会雑誌 Vol. 24 (2013) No. 2:105−115.

29. 射場敏明, 田部陽子. 敗血症性DICに対する抗凝固療法の実際. 日本検査血液学会雑誌 2015,16(2):115-20.

30. 射場敏明, 小倉裕司, 松田直之, 松嶋麻子, 澤村淳, 廣瀬智也, 坂本壮. 日本版重症敗血症診療ガイドライン2016作成に向けて　DIC対策:最近の話題と動向. ICUとCCU 2015;39(8):471-475.
31. 射場敏明. 動物DICモデルから学ぶDICの病態と治療. 血栓と循環 2015;23(2):84-88.

32. 射場敏明. 急性期DICの診療指針. 救急医学 2015;39(11):1544-1549.

33. 射場敏明. DIC対策. 救急・集中治療 sepsis・SIRS　2015,27(11):945-948.

34. 射場敏明. 敗血症性凝固異常における好中球細胞死の関与とDAMPs測定によるそのモニタリング. 体液・代謝管理 2015;31:35-40.

35. 射場敏明. 凝固線溶障害とDIC. 救急・集中治療レビュー 2016-17. 総合医学社 2016; 352-356.

36. 射場敏明. 好中球が関与する凝固の活性化と血栓形成. 血栓止血誌 27(3):308-315.

37. 射場敏明. グリコカリクスが関与する血管内腔の抗血栓性とそのその障害. 血栓止血誌 27(4):444-449.

38. 射場敏明, 渡邉心. 生体侵襲と細胞死. Thrombosis Medicine 6(3):5-10.

39. 射場敏明. DICの病態・診断トピックス. 救急医学 40:951-954.

40. 射場敏明. 国際血栓止血学会レポート (ISTH16). Thrombosis Medicine 6(3):66-68.

41. 射場敏明. アンチトロンビン濃縮製剤. 救急・集中治療アドバンス/重症患者における炎症と凝固・線溶系反応. 中山書店 2017; 352-356.

42. 射場敏明. 救急領域で用いられる薬. 疾病の回復を促進する薬. 放送大学教育振興会 2017; 4433: 210-224.

43. 射場敏明. 生体侵襲と好中球細胞死反応, そして細胞死による凝固・炎症の制御. 外科と代. 謝・栄養 2017 51(1): 1-7.

44. 射場敏明. アンチトロンビンによるDIC治療. Thrombosis Medicine 7(2):66-70.

45. 射場敏明. 深部静脈血栓症を簡便にスクリーニングするには？日本医事新報 2017;4859:58-59.

46. 射場敏明. 感染と細胞死. Coagulation & Inflammation 2017 3(1):19-25.

47. 射場敏明. 炎症と凝固の相互作用. 血液内科 2017;75(5)566-571.

48. 射場敏明. 凝固線溶異常の最新知見. ICUとCCU. 2018;42(1):17-23.

49. 射場敏明. 播種性血管内凝固症候群(DIC)の治療方針. 救急・集中治療最新ガイドライン2018-'19, pp52-54.

50. 射場敏明. 侵襲から臓器不全に至るメカニズム. 救急診療指針改定第5版救急医学会指導医・専門医

51. 射場敏明. 生体侵襲と血管内皮細胞機能. Thrombosis Medicine 8(1):11-16,2018.

52. 射場敏明. 欧米のガイドライン. 救急・集中治療vol 30 臨時増刊号2018 徹底ガイドDICのすべて

53. 射場敏明. アンチトロンビン製剤. 血栓止血誌 2019;30(1):228-232.

54. 射場敏明. グリコカリックス障害と臓器微小循環. 血栓止血誌 2019;30(5):726-732.

55. 射場敏明. 抗凝固薬とDIC: ガイドラインによる推奨度の相違. Thrombosis Medicine 2019;9(2):69-72.

56. 射場敏明. DIC診療の未来ーSCARLET has not gone with the wind. 医学と薬学 201976(7):995-998.

57. 射場敏明. DIC成立過程と基礎疾患. Thrombosis Medicine 2019;9(3):68-71.

58. 射場敏明. ISTH/DIC SSC 2019レポート. Thrombosis Medicine 2019;9(3):89-92.

59. 射場敏明, 相星淳一. 大量輸血に際してのmassive transfusion protocolと大量輸血にまつわる諸問題. 日外会誌 2020;121(4):454-457.

60. 射場敏明. 播種性血管内凝固症候群(DIC)の治療指針. 救急・集中治療最新ガイドライン2020-'21, pp53-55.

61. 射場敏明. DIC診断基準の国際間比較. Thrombosis Medicine 2019;9(4):77-80.

62. 射場敏明. 2020年を迎えて考えるDIC研究の展望. Thrombosis Medicine 2020;10(1):73-76.

63. 射場敏明. ビタミンC静注は急性呼吸窮迫症候群症候群合併セプシスの臓器障害を改善せず. MMJ 2020;16(2)41.

64. 射場敏明. 敗血症に起因する凝固障害と播種性血管内凝固(DIC). 麻酔 2020;69:740-748.

65. 射場敏明. COVID-19凝固異常症　抗凝固療法, 線溶・抗線溶療法. Thrombosis Medicine. 2021;11(3):200-206.

66. 射場敏明. COVID-19患者への早期の予防量hパリン投与死亡率を低下させる可能性. MMJ. 2021;17(5):139.

67. 射場敏明. 日本版敗血症診療ガイドライン2020の注目すべきトピックス: DIC診断と治療. ICUとCCU. 2021;45(9):579-587.

68. 射場敏明. 播種性血管内凝固症候群(DIC)の治療指針. 救急・集中治療最新ガイドライン2022-'23, pp55-58. (総合医学社)

69. 射場敏明. COVID-19ワクチンによるTTSの推定発生機序. Cardio-Coagulation. 2022;9(1):22-27. (メディカルレビュー社)

70. 射場敏明. 救急現場のDAMPs, PAMPsとRAMPs. Thrombosis Medicine. 2022;12(1):47-51. (先端医学社)

71. 射場敏明. COVID-19に対する抗血栓療法. Land-Mark in Thrombosis&Haemostasis. 2022;2:107-110. (メディカルレビュー社)

72. 射場敏明. 徹底ガイドDICのすべて2022-'23: 欧米のガイドライン. 救急・集中治療. 2022;34(2):704-709. (総合医学社)

73. 射場敏明. 徹底ガイドDICのすべて2022-'23: 日本版敗血症診療ガイドライン2020とDIC. 救急・集中治療. 2022;34(2):715-723. (総合医学社)

74. 射場敏明. 徹底ガイドDICのすべて2022-'23: アンチトロンビン. 救急・集中治療. 2022;34(2):862-867. (総合医学社)

75. 射場敏明. 血栓症と炎症：多臓器不全・多様な症状への進行機序. 医学のあゆみ. 2021;279(11):1115-1119.

研究者

教育活動

【学校法人順天堂】研究者情報データベース

研究業績詳細

射場 敏明（イバ トシアキ）

射場敏明（イバトシアキ）